From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story? The author derives significant innovative determinants of success for both strategies.
Contents: The Pharmaceutical Industry and its Paradigm Shift - The Pharmaceutical Industry and Mergers & Acquisitions - Value Creation in Pharmaceutical M&A and its underlying Value Drivers - The Pharmaceutical Industry and Alliances - Value Creation in Pharmaceutical In-licensings and its underlying Value Drivers - M&A versus In-licensing.